All In Biotech

Drug Trial Radar · NCT02421926

Extension Study of IDEAL (Imatinib) for Chronic Myelgenous Leukemia (CML)

Extension Study of a Study to Evaluate Efficacy and Safety of Imatinib (Glinib®) 600mg/Day Depending on Early Molecular Response in Newly Diagnosed Patients With Chronic Myeloid Leukemia in Chronic Phase

Last checked: Nov 19, 2026Latest source record: Jul 8, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Withdrawn

Status

Withdrawn

Enrollment

0

Actual

Start

Oct 2014

Primary completion

May 2023

Study completion May 2023

Sponsor

Lead sponsor
Asan Medical CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Apr 21, 2015

More drug trials from this sponsor

Design

Study type
Observational
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is an extension study (prospective observational study) of 'IDEAL' study (A Study to Evaluate Efficacy and Safety of Imatinib (Glinib) 600mg/day depending on Early Molecular Response in Newly Diagnosed Patients with Chronic Myeloid Leukemia in Chronic Phase, NCT02204722) to evaluate the duration of treatment response, disease progression, and survival status up to 5 years after the inclusion.

Conditions

  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Interventions

  • IDEAL-E observation (investigators choice of imatinib, nilotinib, dasatinib, radotinib)Drug

    After the end of follow-up period of IDEAL study, subjects who agree with this extension study (IDEAL-E) will be enrolled and be followed up for additional 4 years to evaluate the duration of treatment response, disease progression, and survival status. Subjects who will be enrolled in this prospective observational study will be treated with drugs - imatinib 300-600mg / nilotinib 600mg / dasatinib 100mg / radotinib 800mg - which has been chosen by the each investigator according to the drug compliance and overall response. The drug choice will be at the discretion of each investigator, and the overall adverse event / molecular response will be monitored every 6 months in this prospective observational study.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. progression-free survival rateTime frame: 5-year

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • Korea University Ansan Hospital

    Ansan, South Korea

  • Busan National University Hospital

    Busan, South Korea

  • Haeundae Paik Hospital

    Busan, South Korea

  • Chungnam National University Hospital

    Daejeon, South Korea

  • Gachon University Gil Hospital

    Incheon, South Korea

  • Asan Medical Center

    Seoul, South Korea

  • Korea University Anam Hospital

    Seoul, South Korea

  • Korea University Guro Hospital

    Seoul, South Korea

  • Seoul National University Hospital

    Seoul, South Korea

  • Soonchyunhyang University Hospital

    Seoul, South Korea

  • Ajou University Hospital

    Suwon, South Korea

  • Seoul National University Bundang Hospital

    Seongnam, Gyong-gi Province, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.